RU2015148359A3 - - Google Patents

Download PDF

Info

Publication number
RU2015148359A3
RU2015148359A3 RU2015148359A RU2015148359A RU2015148359A3 RU 2015148359 A3 RU2015148359 A3 RU 2015148359A3 RU 2015148359 A RU2015148359 A RU 2015148359A RU 2015148359 A RU2015148359 A RU 2015148359A RU 2015148359 A3 RU2015148359 A3 RU 2015148359A3
Authority
RU
Russia
Application number
RU2015148359A
Other languages
Russian (ru)
Other versions
RU2015148359A (ru
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033727 external-priority patent/WO2014169167A1/en
Publication of RU2015148359A publication Critical patent/RU2015148359A/ru
Publication of RU2015148359A3 publication Critical patent/RU2015148359A3/ru

Links

RU2015148359A 2013-04-12 2014-04-11 Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor RU2015148359A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811408P 2013-04-12 2013-04-12
US61/811,408 2013-04-12
PCT/US2014/033727 WO2014169167A1 (en) 2013-04-12 2014-04-11 Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways

Publications (2)

Publication Number Publication Date
RU2015148359A RU2015148359A (ru) 2017-05-15
RU2015148359A3 true RU2015148359A3 (enExample) 2018-01-31

Family

ID=50771612

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015148359A RU2015148359A (ru) 2013-04-12 2014-04-11 Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor

Country Status (13)

Country Link
US (5) US9499495B2 (enExample)
EP (1) EP2984088B1 (enExample)
JP (1) JP6496301B2 (enExample)
KR (1) KR20150143672A (enExample)
CN (1) CN105283454B (enExample)
AU (1) AU2014250836C1 (enExample)
BR (1) BR112015025901A8 (enExample)
CA (1) CA2909310A1 (enExample)
IL (2) IL242020B (enExample)
MX (1) MX2015014387A (enExample)
RU (1) RU2015148359A (enExample)
WO (1) WO2014169167A1 (enExample)
ZA (1) ZA201507750B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP2019519593A (ja) * 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
EP4169918B8 (en) 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239075B (zh) * 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
US11318137B2 (en) 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling
KR102736865B1 (ko) * 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
US10695296B2 (en) * 2017-07-14 2020-06-30 Asana Biosciences, Llc Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
CN108623582A (zh) * 2017-10-10 2018-10-09 河南省锐达医药科技有限公司 一类新型含取代基吡啶并嘧啶化合物的制备方法
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
CN112341434B (zh) * 2019-08-08 2021-11-26 恩瑞生物医药科技（上海）有限公司 PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
MX2022005229A (es) 2019-11-01 2022-06-08 Fmc Corp Un nuevo proceso eficaz para la sintesis de 2-amino-5-cloro-n,3-di metilbenzamida.
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
PE20231311A1 (es) * 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
CN113416181B (zh) * 2021-08-02 2022-05-03 四川大学 喹唑啉类衍生物及其用途
IL310931A (en) * 2021-09-10 2024-04-01 Black Diamond Therapeutics Inc 6-aza-quinoline derivatives and related uses
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250084078A1 (en) * 2022-01-04 2025-03-13 Genfleft Therapeutics (Shanghai) Inc. Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof
CN115894211A (zh) * 2022-11-10 2023-04-04 山东龙立恒医药有限公司 一种3-羟基-4-甲基苯甲酸的制备方法
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2010539239A (ja) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
WO2011097526A1 (en) * 2010-02-05 2011-08-11 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Similar Documents

Publication Publication Date Title
BR112021000792B8 (enExample)
AT524874A5 (enExample)
AT524834A2 (enExample)
AU2018438767B1 (enExample)
AT521543A3 (enExample)
AT524266A2 (enExample)
BR102019026286B1 (pt) Método e aparelho para o avanço de produtos a serem moldados
BR102019025884B1 (pt) Sistema de segurança aprimorado para máquinas de operação de autopropulsão
BR102019023514B1 (pt) Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna
BR112020016338B1 (pt) Dispositivo para tratamento de tecido corporal
BR112021001374B1 (pt) Composição farmacêutica para o tratamento da hipertensão e seu uso
BR112021001128B1 (pt) Composição de cimento para impressão 3d, método de impressão 3d, kit para a preparação de uma composição de cimento para impressão 3d e método de impressão 3d implementando o kit
BR112021001186B1 (pt) Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos
BR112021000922B1 (pt) Tela de filtro, e, método para purificar água de alimentação
BR112020026077B1 (pt) Recipiente com estrutura encaixável
BR112020026721B1 (pt) Aparelho de moldagem para modar uma folha de um material contendo alcaloides
BR102019012845B1 (pt) Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga
BR112020023832B1 (pt) Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral
BR112020024987B1 (pt) Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico
BR112020023823B1 (pt) Distribuidor
BR112020022482B1 (pt) Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico
BR112020022658B1 (pt) Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido
BR112020022516B1 (pt) Processo para degomagem enzimática de óleo
BR112020021042B1 (pt) Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas
BR112020020812B1 (pt) Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado